Therapeutic in vivo delivery of gene editing agents
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2022/07/01
-
Journal
-
Indian UGC (journal)
-
Refrences226
-
Citations127
-
Aditya Raguram
-
Samagya Banskota
-
David R. Liu ORCID (unauthenticated)
Cite
Raguram, Aditya, et al. “Therapeutic in vivo Delivery of Gene Editing Agents”. Cell, vol. 185, no. 15, 2022, pp. 2806-27, https://doi.org/10.1016/j.cell.2022.03.045.
Raguram, A., Banskota, S., & Liu, D. R. (2022). Therapeutic in vivo delivery of gene editing agents. Cell, 185(15), 2806-2827. https://doi.org/10.1016/j.cell.2022.03.045
Raguram, Aditya, Samagya Banskota, and David R. Liu. “Therapeutic in vivo Delivery of Gene Editing Agents”. Cell 185, no. 15 (2022): 2806-27. https://doi.org/10.1016/j.cell.2022.03.045.
Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell. 2022;185(15):2806-27.
Journal Categories
Science
Biology (General)
Science
Biology (General)
Cytology
Science
Biology (General)
Genetics
You May Also Like
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- Regulation of chromatin by histone modifications
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases
- RNA-Seq: a revolutionary tool for transcriptomics
- Network biology: understanding the cell's functional organization
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
CAR T cells produced in vivo to treat cardiac injury | Science |
| 435 | 2022 |
| Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges | Journal of Controlled Release |
| 74 | 2022 |
| Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases | Cell |
| 104 | 2022 |
| Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins | Cell |
| 222 | 2022 |
| CRISPR-based genome editing through the lens of DNA repair | Molecular Cell |
| 70 | 2022 |
Refrences Analysis
The category
Science: Biology (General): Genetics 93
is the most frequently represented among the references in this article. It primarily includes studies from Nature Biotechnology and Nature Communications. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Bispecific, Exosome‐Mimetic Lipid Nanoparticles Facilitate Dual siRNAs for Synergistic Therapy against Pancreatic Cancer | Advanced Functional Materials |
| 2024 | |
Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR‐Cas12f1 System Delivered with All‐in‐One Adeno‐Associated Virus | Advanced Science |
| 2024 | |
Developing a Novel Enzalutamide‐Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells | Current Protocols |
| 2024 | |
Gene doping detection in the era of genomics | Drug Testing and Analysis |
| 2024 | |
Temperature/GSH Dual Responsive Fluorinated Mesoporous Silica‐Coated Au NRs for Serum‐Resistant Gene Delivery** | ChemistrySelect |
| 2024 |
Citations Analysis
The category
Science: Biology (General) 34
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled CRISPR-Based Tools for Fighting Rare Diseases and was published in 2022. The most recent citation comes from a 2024 study titled A Guanidinobenzol-Rich Polymer Overcoming Cascade Delivery Barriers for CRISPR-Cas9 Genome Editing. This article reached its peak citation in 2023, with 79 citations. It has been cited in 95 different journals, 33% of which are open access. Among related journals, the Nature Communications cited this research the most, with 7 citations. The chart below illustrates the annual citation trends for this article.